Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus.
暂无分享,去创建一个
P. Marquet | M. Oellerich | P. Wallemacq | J. Gaulier | D. Wilson | F. Johnston | D. Holt | M. Moreton | J. Engelmayer | H. Luthe | D. Moscato | R. Mosso | F. Streit | M. Brunet | C. Fillée | R. Schmid | G. Barnes
[1] D. Holt,et al. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. , 2004, Transplantation proceedings.
[2] D. Cooper,et al. High-Throughput Liquid Chromatography-Tandem Mass Spectrometric Analysis of Sirolimus in Whole Blood , 2003, Clinical chemistry and laboratory medicine.
[3] W. Bablok,et al. A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I , 1983, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.
[4] L. Shaw,et al. Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. , 2000, Clinical therapeutics.
[5] Cass J. Grandone,et al. The Abbott IMx automated benchtop immunochemistry analyzer system. , 1988, Clinical chemistry.
[6] B. Kahan,et al. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection. , 1996, Clinical chemistry.
[7] G. Barnes,et al. Inter-laboratory differences in sirolimus results from six sirolimus testing centers using HPLC tandem mass spectrometry (LC/MS/MS). , 2005, Clinica chimica acta; international journal of clinical chemistry.
[8] D. Holt,et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. , 2003, Transplantation proceedings.
[9] H. Meier‐Kriesche,et al. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. , 2000, Clinical therapeutics.
[10] P. Taylor,et al. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[11] D. Holt,et al. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. , 2000, Clinical therapeutics.
[12] H. Schiebel,et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[13] S. Maleki,et al. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. , 2000, Clinical therapeutics.
[14] H. Schiebel,et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. , 1996, Clinical chemistry.
[15] U. Christians,et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.
[16] D. Holt,et al. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. , 2000, Clinical chemistry.
[17] B D Kahan,et al. Clinical Pharmacokinetics of Sirolimus , 2001, Clinical pharmacokinetics.
[18] V. Armstrong,et al. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. , 2002, Clinical chemistry.
[19] N. Nakashima,et al. Analytical Performance of Microparticle Enzyme Immunoassay and HPLC-Tandem Mass Spectrometry in the Determination of Sirolimus in Whole Blood , 2022 .
[20] N. Perico,et al. Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[21] D. Holt,et al. An immunoassay for the measurement of sirolimus. , 2000, Clinical therapeutics.
[22] U. Christians,et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. , 1998, The Journal of pharmacology and experimental therapeutics.
[23] P. Taylor,et al. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. , 2000, Clinical therapeutics.
[24] H. Schiebel,et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[25] J. Zimmerman,et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. , 2000, Clinical therapeutics.